Foldable toric IOL safe and effective in high astigmatism

Article

According to Omid Kermani from the Augenabteilung der PAN-Klinik am Neumarkt, Köln, Germany, and colleagues, the implantation of a foldable toric intraocular lens (IOL) is a safe and predictable procedure for the correction of high pre-existing corneal astigmatism in cataract surgery.

According to Omid Kermani from the Augenabteilung der PAN-Klinik am Neumarkt, Köln, Germany, and colleagues, the implantation of a foldable toric intraocular lens (IOL) is a safe and predictable procedure for the correction of high pre-existing corneal astigmatism in cataract surgery.

A total of 58 eyes were implanted with the MS 6116 TU IOL (HumanOptics) lens during a retrospective study. The IOL has a 6 mm silicon optic with a toric rear surface and the PMMA-haptics are undulated with a Z-shaped design to prevent secondary rotation. Average preoperative astigmatism was 3.75 D.

Postoperatively, astigmatism was reduced to 0.84 D and surgically induced astigmatism was less than 0.5 D in all cases. 85% of the IOLs remained stable within 10° of the target axis. In 5% of the eyes, secondary rotation was performed three to six weeks postoperatively.

Kermani and his colleagues concluded that implantation of HumanOptics' foldable toric IOL is both safe and effective in treating high corneal astigmatism in cataract surgery.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.